Articles

Find an Article

Filter articles

Applied Filters

Showing 251 to 260 of 288 results

New frontiers: potential barriers to patenting induced totipotent stem cell technology

EU04-11-2013

Ethical considerations plus the ambiguity of the Biotech Directive are factors influencing the patentability of totipotent stem cells, says Andrew Sanderson.

New horizons: biotech guidelines in Brazil

Brazil16-10-2013Gabriel Di Blasi and Alexandre Santos

New guidelines for the examination of biotechnology inventions in Brazil provide useful support for applicants, as Gabriel Di Blasi and Alexandre Santos explain.

Protecting plant products in Europe

EU16-10-2013Frances Salisbury and Lindsey Woolley

Frances Salisbury and Lindsey Woolley look at the complex business of patenting agricultural products in Europe.

Patents for self-replicating products: not so exhausting after all

EU16-10-2013

When the US Supreme Court decided in favour of Monsanto in its case against a soybean farmer, it clarified the patent status of certain self-replicating technologies. In Europe, the result would probably have been the same, say Steven Zeman and Heike Vogelsang-Wenke.

Salad days: tomatoes, broccoli and radish patents

EU16-10-2013Margreet van Heuvel and Bart Swinkels

When it comes to plants, European courts have been occupied with various debates over salad. Margreet van Heuvel and Bart Swinkels take a look.

Courting controversy: the implications of Brüstle

EU, Germany16-10-2013

The Court of Justice of the European Union’s decision in the Brüstle case has worrying implications for some stem cell patents. Andy Sanderson looks at the landscape across Europe.

Teaching old drugs new tricks

US30-09-2013

Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach.

Big player: the Bavarian biotech cluster

Germany30-09-2013

With a track record of successful innovation, Munich is one of the leading lights of European biotech. LSIPR went to visit.

Keeping secrets: protecting the smallpox vaccine

31-07-2013

Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out.

Current barriers to biotech in Brazil

Brazil31-07-2013Gabriel Di Blasi

Gabriel Di Blasi outlines the existing impediments to developing new biotechnology products in Brazil, and considers recent efforts to improve the situation.

Showing 251 to 260 of 288 results

LSIPR